Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698464 | 0.84 | ABCB1 (0.62) | MEN1KMT2AGLAKDM4EALDH1A1 | |
| SCHEMBL13698472 | 0.84 | HSD17B10 (0.51) | MEN1KMT2AGLAKDM4EALDH1A1 | |
| SCHEMBL5460658 | 0.83 | GAA (0.62) | MEN1KMT2AGLAKDM4EALDH1A1 | |
| SCHEMBL13698476 | 0.82 | ALDH1A1 (0.70) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL14768684 | 0.80 | KDM4E (0.51) | MEN1KMT2AGLAKDM4EALDH1A1 | |
| SCHEMBL13468008 | 0.79 | L3MBTL3 (0.59) | MEN1KMT2AGLAKDM4EABCB1 | |
| SCHEMBL999259 | 0.77 | GAA (0.47) | MEN1KMT2AGLAKDM4EALDH1A1 | |
| SCHEMBL27851348 | 0.77 | GAA (0.47) | MEN1KMT2AGLAKDM4EALDH1A1 | |
| SCHEMBL737747 | 0.77 | GRIN2B (0.65) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL13240777 | 0.77 | GRIN2B (0.65) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | MEN1 3939/4885KMT2A 1668/4885GLA 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.